Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Telix Pharmaceuticals Limited due to allegations of misleading statements and undisclosed information regarding the company's prostate cancer therapeutic candidates and supply chain issues [2][5]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses in Telix between February 21, 2025, and August 28, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Telix, with a deadline of January 9, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Telix and its executives violated federal securities laws by making false statements and failing to disclose critical information about the company's progress and supply chain quality [5]. Group 2: Impact of Regulatory Actions - On July 22, 2025, Telix disclosed receiving a subpoena from the U.S. Securities and Exchange Commission, leading to a more than 13% drop in the price of its American Depositary Shares over two trading sessions [6]. - On August 28, 2025, Telix announced receiving a Complete Response Letter from the U.S. Food and Drug Administration regarding its product TLX250-CDx, which identified deficiencies in the Chemistry, Manufacturing, and Controls package, resulting in a more than 21% decline in share price over two trading sessions [7]. Group 3: Class Action Participation - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members and oversees the litigation [8]. - Any member of the class may move to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [9].
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals